Novartis AG opened higher at $162.53, compared with its previous close of $161.10. In the last trading session, the stock traded between $161.94 and $164.06. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Novartis AG is now worth
$ 196.47
giving a profit of
$ 96.47 (96.47%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
+$1.50 (+0.93%)
Day High
$164.06
Day Low
$161.94
Day Open
$162.53
Prev Close
$161.10
Volume
10,07,518
1W Return
4.05%
1M Return
11.60%
3M Return
2.38%
6M Return
13.75%
1Y Return
33.50%
Market Cap ($ Mn)
3,30,862
PE Ratio
23.23
PB Ratio
7.04
PEG Ratio
2.14
ROE
32.50%
ROCE
22.92%
EPS (TTM)
$0.64
1 Week
4.05%
1 Month
11.60%
3 Months
2.38%
6 Months
13.75%
9 Months
9.19%
Pomerantz investigates Novartis after Phase III trial failure
Pomerantz LLP is investigating Novartis AG for potential securities fraud following the failure of its Phase III HARBOR study for del-desiran. The study for myotonic dystrophy type 1 failed to show statistically significant improvement versus placebo on the primary endpoint of video hand opening time. Novartis ADS prices fell $22.29, or 13.93%, to close at $137.70 on September 8, 2026, following the announcement.
16 days agoPomerantz investigates Novartis claims after trial failure hits stock
Pomerantz LLP investigates Novartis AG for potential securities fraud. ADS price fell $22.29 (13.93%) following Phase III HARBOR trial failure. Trial evaluated del-desiran for myotonic dystrophy type 1. Investors advised to contact Pomerantz LLP to join class action.
29 days agoNovartis halts ALS trial, acquires Sironax brain platform for $125m
Novartis terminated VHB937 ALS trial after missing primary/secondary endpoints. Company exercised $125 million option to acquire Sironax brain delivery platform. VHB937 development continues for Alzheimer's disease despite ALS failure. Sironax retains rights to develop specific assets using the acquired technology.
1mo agoNovartis, BMY halt autoimmune CAR-T trials after safety deaths
Novartis and BMY halted autoimmune CAR-T trials due to severe adverse events and deaths. BMY delayed public disclosure of its trial pause by three months after notifying regulators. Novartis confirmed three patient deaths only after external analysts detected database changes. Manufacturing differences may influence toxicity risks between the two therapies. Shares fell with Novartis down 1.58% and BMY down 1.73% on Friday.
1mo agoNovartis shares rise 5.86% on positive Phase 3 MS drug results
Novartis shares rose 5.86% to $160.97 on positive Phase 3 data for remibrutinib. Remibrutinib significantly reduced annualized relapse rates vs teriflunomide in two trials. First BTK inhibitor to show this efficacy across two Phase 3 studies for relapsing MS. No liver safety signal observed in program with over 4,500 participants. William Blair notes growing competition from Roche's fenebrutinib and Sanofi's frexalimab.
1mo agoNovartis beats estimates as priority medicines drive Q2 revenue
Novartis AG reported Q2 adjusted EPS of $2.41, beating estimates, with revenue rising to $14.41 billion. Priority medicines drove growth, offsetting generic competition, while the company reaffirmed its 2026 guidance.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 | |
| $43.13 | +2.11% | $1,04,182.50M | 23.63 |
An investment of $100 made 5 years ago in Novartis AG is now worth
$ 196.47
giving a profit of
$ 96.47 (96.47%)
Note: Past profits do not guarantee future returns.
